Cancer Research · Biotechnology

Where do you think the circulating tumor cell market will be in the short, medium and long term?

John Butler Founder and President at Quantumcyte, Inc, Director of Process Development at Stanford University School of Medicine

July 22nd, 2015

Cancer research focused on circulating tumor cells has gained a lot of steam in the past 5 to 10 years.  Most products are focused on isolation of these rare cells from blood with >30 products on the market focused solely on isolation.  I am interested in getting this groups perspective on where this market will be heading.

Onikepe Adegbola, MD PhD

July 24th, 2015

I remember the first time I heard the hype on CTCs, about 8 years ago, when I was in pharma and we were using it as an exploratory marker. Things have not moved much since then, as far as I can tell. It is still in the research mode, slowly moving into clinical use, but a number of barriers remain - standardization (what is a CTC? What is the best way to extract them? There are so many conflicting technologies, it is difficult to compare data), convincing clinical trial data, etc. In short I think it will remain mostly research in the short and medium term.
Here's a brief summary of the problems faced by a company in the space: http://lifescivc.com/2013/04/on-q-ity-a-cancer-diagnostic-company-r-i-p/

Vijay MD Founder Chefalytics, Co-owner Bite Catering Couture, Independent consultant (ex-McKinsey)

July 22nd, 2015

My guess would be diagnostics marker first, biopsy substitute second, treatment vector 3rd (as any cocktail that eliminated metastatic spread should take out core tumor as well.  Long road...and as in all things cancer, likely to face institutional resistance more than technical hurdles on the path to adoption.       

Karl Schulmeisters CTO ClearRoadmap

July 23rd, 2015

When you say "market"  do you mean

  • Detection?
    • In Hospital
    • By mHealth device
  • Treatment?
    • Conventional,
    • advanced "personalized medicine"?

Each of these are different market segments and different investment types

Maxine Pierson INTERIM CEO, EXECUTIVE DIRECTOR/ VP Investor

May 23rd, 2016

As a layperson on the investor / educational/   delivery side - I believe we are only hampered by publicity and a national presence to provide funding; I am especially close to the gliablastoma problem; we need a Ted Kennedy / Bo Biden image /presence Foundation to be the figurehead.Most people do not know that clinical trial participation is not for the weak - or the poor .I was able to get an airline to provide free fare for trail participants and a caregiver- but it is a nightmare - financially and emotionally - and you are at best still rolling the dice ...Sorry to be so negative .  

Joshua Falcon-Grey Creative Leadership Trainer/Speaker and Immersive Media Developer

May 23rd, 2016

The industry will be changing rapidly at the mainstream starts to understand that cancer cures have been around for many years. It can be approached psychologically, supplementally, energetically - a variety of doorways. In essence, we all have out of control cancer cells that grow every single day and our immune system is designed to target and eliminate them. When our immune system is too weak, this cycle doesn't work properly. There's currently a docu-series circulating on this topic if you haven't seen it:thetruthaboutcancer.com/category/videos

Maxine Pierson INTERIM CEO, EXECUTIVE DIRECTOR/ VP Investor

May 22nd, 2016

Dear Dr.  Goel- As a mere layperson -A question if you please : As do I  believe  all tumors (exactly alike in totally different  ways) have the same growth roadmap for self creation  (vein system- etc) is there not a system of "road spikes " we can erect at the beginning to  have a universal "stop sign -if you will?
Thank you very much.-Best Regards,

Maxine Pierson

Executive Director

PH: 561-292-3824

FAX: 866-380-6568

www.STRATEGICBUSINESSINSTITUTE.ORG
 -=